Showing results (51-60 of 102) with videos related to
Sort By:
Pageof 11
BMC Gastroenterology|July 4, 2014
FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis BMarija Zeremski, Rositsa B Dimova, Samantha Benjamin, et al.Harm Reduction Journal|March 5, 2025
Breaking the vicious cycle of delayed healthcare seeking for people who use drugsZoi Papalamprakopoulou, Elisavet Ntagianta, Vasiliki Triantafyllou, et al.The Journal of Infectious Diseases|November 4, 2005
Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virusKristen M Marks, Lydia M Petrovic, Andrew H Talal, et al.BMC Medical Informatics and Decision Making|October 18, 2024
Telehealth to increase healthcare access; perspectives of people who use drugsZoi Papalamprakopoulou, Elisavet Ntagianta, Vasiliki Triantafyllou, et al.Contemporary Clinical Trials|November 23, 2021
Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C)Andrew H Talal, Marianthi Markatou, Elisavet M Sofikitou, et al.JAMA|April 3, 2024
Integrated Hepatitis C-Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized TrialAndrew H Talal, Marianthi Markatou, Anran Liu, et al.Journal of Addiction Medicine|February 17, 2016
Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational InterventionMarija Zeremski, Roberto Zavala, Rositsa B Dimova, et al.Journal of Hepatology|April 7, 2007
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirinHarel Dahari, Marianthi Markatou, Marija Zeremski, et al.BMC Health Services Research|April 11, 2025
Considerations for equitable distribution of digital healthcare for people who use drugsZoi Papalamprakopoulou, Sotirios Roussos, Elisavet Ntagianta, et al.Hepatology (Baltimore, Md.)|June 9, 2006
Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonrespondersAndrew H Talal, Ruy M Ribeiro, Kimberly A Powers, et al.Pageof 11